SINTX Q3 net loss narrows 55% to $1.6 million; Q3 revenue rises to $2.2 million

• SINTX Technologies' third-quarter 2026 net loss narrowed 55% to approximately $1.6 million, while revenue rose to approximately $2.2 million.
• Gross margin climbed to approximately 62% from 45%, reflecting improved pricing, higher manufacturing volumes and increased production efficiencies.
• Quarter-end cash totaled approximately $2 million; subsequent Class B warrant exercises generated approximately $2 million in gross proceeds.
• Initial commercial sales of the FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System are underway following completion of its limited-use release.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SINTX Technologies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-050224), on November 05, 2026, and is solely responsible for the information contained therein.